Syneos Health (SYNH), which previously was working with investment bank Centerview Partners to explore a sale before the market disruption triggered by the onset of the COVID-19 pandemic prompted it to abandon those sale deliberations, is now making a new effort to sell itself and has hired Bank of America (BAC) in addition to Centerview as financial adviser as it embarks on a new round of talks with potential acquirers, reported Reuters’ David Carnevali and Anirgan Sen, citing sources.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SYNH:
- Syneos Health Unveils New Decentralized Clinical Trial Site Network to Drive DCT Adoption
- Syneos Health price target raised to $51 from $42 at Baird
- Syneos Health Reports Fourth Quarter and Full Year 2022 Results
- Syneos Health sees FY23 adjusted EPS $3.26-$3.53, consensus $3.89
- Syneos Health reports Q4 adjusted EPS $1.23, consensus $1.20